



# Planning & Analytics for Total Health

Deliver actionable analytics and prescriptive strategies

## Virginia Bankers Association

Prior: Jan 2023 - Dec 2023

Current: Jan 2024 - Dec 2024

## Reporting Parameters – MMA Book of Business

## **Reporting Period**

Paid during the following periods:

Current:

Jan 2024 - Dec 2024

Prior:

Jan 2023 - Dec 2023

Data does not include Sona Bank or Atlantic Union Bank

## Settings

Includes inpatient facility, outpatient facility and professional claims

Stop loss reimbursements and pharmacy rebates are not included in this data.

High-Cost Claimants are defined as those greater than \$100,000.

## Benchmarking

Benchmarking is MMA Book of Business which consists of approximately **one million member lives.** The benchmarking is not categorized based on your population's demographics.

## **Risk Scoring**

Wakely Risk Assessment (WRA) is the measure of risk associated with an individual's age, gender, and conditions, relative to an average person.

A relative risk score of 1.00 is average and an individual with an RRS of 1.50 is predicted to spend 50% more in resources compared to the average person.

## Generations at a Glance

Born

Age

% of your group's population

Communication preference

**Aspirations** 

Motivated by

## **Utilization Metrics**


Preventive Visits/1000

PCP Visits/1000

Telemedicine Visits/1000

ER Visits/1000

Urgent Care Visits/1000






## **Cost & Enrollment**









## **Cost Trends**

	01/22-12/22	01/23-12/23	01/24-12/24	2 Year Trend	3 Year Trend	Benchmark
Medical Plan	\$39,241,538	\$35,744,575	\$37,430,994	5%	-5%	-
Pharmacy Plan	\$15,050,526	\$15,868,133	\$16,412,125	3%	9%	-
Total Plan	\$54,292,064	\$51,612,708	\$53,843,119	4%	-1%	-
Med PMPM	\$362	\$335	\$388	16%	7%	\$433
Pharmacy PMPM	\$139	\$149	\$170	15%	22%	\$165
Total PMPM	\$501	\$483	\$559	16%	12%	\$599

## Previous: 01/23-12/23 | Current: 01/24-12/24

Spouses have the highest Medical/Rx PMPM, spouses also have the highest risk scores.

Members >60yr. old (1,544 total):Total Employer Paid Amount of \$15.2M.

Members <60yr. old (7,965 total):Total Employer Paid Amount of \$38.7M

Consider Medicare Education Programs.

Medical drivers of trend increase were HCC's and Inpatient Admission costs

Pharmacy trend increases were specialty medications, specifically cancer medications, Stelara and Humira.



## **Utilization**

## Utilization Trends

Utilization per 1k	01/22-12/22	01/23-12/23	01/24-12/24	2 Year Trend	3 Year Trend	Benchmark
PCP visits	2,101	2,054	2,163	5%	3%	1,779
Specialist visits	1,311	1,332	1,353	2%	3%	1,310
Telemedicine visits	648	642	760	18%	17%	708
Urgent care visits	271	287	308	8%	14%	243
Emergency Visits	146	144	170	18%	16%	193
Outpatient Surgeries	96	105	105	0%	9%	112
Inpatient Admits	40	33	35	6%	-13%	53

## 00

## **Pharmacy Utilization**

Utilization per 1k	01/22-12/22	01/23-12/23	01/24-12/24	2 Year Trend	3 Year Trend	Benchmark
Scripts	10,289	9,841	10,704	9%	4%	
Generic scripts	85%	87%	87%	0%	2%	
Specialty drug spend	51%	51%	52%	1%	1%	

Proprietary and confidential

Marsh & McLennan Agency LLC



## **Insights**

### **Utilization Trends**

HCC utilization increased by 1 member. Medical and Rx paid amount trend increased 21%, net increase of \$3.4M

HCC accounted for 35% of spend, prior period, 30%

ER utilization/cost increased, 18% and 21% respectively, net increase \$264k. Avoidable ER utilization/cost increased 24% and 20%, net increase \$90k. Top diagnoses were urinary tract infection, nausea/vomiting.

 Employees, Gen X, Gen Z and Millennials highest utilizers.

Inpatient Admission utilization increased 6%, costs increased 18%, \$1.6M Average length of stay is 7 days which is above MMA's book of business of 4 days.

### **Pharmacy**

Antidepressants, Statins and Contraceptives were top drug classes by prevalence.

Anti-Rheumatics, GLP-1 Agonists and Psoriasis Agents were top drug classes by spend.


 Anthem adding Humira and Stelara biosimilars to formulary as optional July 2025, consider for Jan 2026


## **Pharmacy Trends**











Planning 8. Analytics for Total Haalth

## **Pharmacy Insight**

Pharmacy PMPM trend increased 15% due to an increase in both the cost per script 6% as well as script utilization 9%.

Specialty accounted for 52% of pharmacy spend, up from the prior period 1%. Script utilization increased 78% while the total paid amount increased 6%,net increase \$+453k.

GLP-1 saw a 36% increase in script utilization; cost increase of 16%. MMA BoB cost trend for 2024 was 45%.

Anti-Rheumatics cost increased. Driver of cost was Humira \$1.6M.

Psoriasis Agents have seen an uptick in cost 17%, specifically Stelara \$1.2M.

Cancer Agents have seen a slight decrease

SGLT-2 Inhibitors are medications for diabetes to assist with lowering blood sugar.

Proprietary and confidential

Marsh & McLennan Agency LLC


## **High-Cost Claim Analysis**


### Members with Med+Rx claims >\$100,000: PP 80 CP 81




Marsh & McLennan Agency LLC

	Prior	Current	% change
Medical Paid HCC	\$11,435,169	\$13,689,208	+20%
Rx Paid HCC	\$4,255,252	\$5,358,010	+26%
Total	\$15,690,421	\$19,047,218	+21%







### **Total Cost**

Medical increase 20% and an increase in pharmacy, 26%.
Total medical and pharmacy trend 21%

### % of Total Spend

HCC accounted for 35% of the overall spend, prior period, 30%

### **Top Diagnosis Chapters**

Factors Influencing health status cost increase driven by twin liveborn infants One of twins is a HCC, however, claims are winding down.

Circulatory and Respiratory diagnoses increased in cost due to #1 HCC with relapsing polychondritis, aneurysm in pulmonary artery, ECMO machine for acute respiratory failure.

### **Top Drug Classes**

Cancer Agents have seen a slight uptick.

Psoriasis agents have seen a significant increase due to Stelara increase \$645k to \$911k, 41%

Anti-Rheumatic Modulators saw a significant increase being driven by Humira, \$257k to \$545k, 112%.

Vasopressor Antagonist costs due to Jynarque, used to slow kidney decline in polycystic kidney disease.


Cystic Fibrosis Agents have seen an uptick

.




## **Cancer Screening Rates**






Prior Period – 72% BoB Benchmark – 65%

### Colon Cancer



Prior Period – 47% BoB Benchmark – 47%

### **Cervical Cancer**



Prior Period – 70% BoB Benchmark – 62%





## **Gene Therapy Risk Assessment**

	Luxturna	Zolgensma	Zynteglo	Skysona	Hemgenix	Adstiladrin
Indicated for	Vision loss	Spinal Muscular Atrophy (SMA) children <2	Blood disorder - Beta Thalassemia	Active cerebral adrenoleukod ystrophy male, children <18	Hemophilia B	Non-invasive bladder intramural cancer (NMBIC)
Estimated cost	\$850,000	\$2,100,000	\$2,800,000	\$3,000,000	\$3,500,000	\$500k-\$750k
Prevalence	1:3,500	1:10,000	1:100,000	1:15,000	1:40,000	18:100,000
Members*	0	0	0	0	1	3

\* A diagnosis is not a quarantee that the member meets gene therapy eligibility requirements or will elect treatment. This number represents the total count of members diagnosed with the specified disease; eligibility is contingent upon various factors including overall health, availability of alternative treatments, specific clinical criteria, and prior authorization requirements.

U	U	U	U		3
Elevidys	Roctavian	Vyjuvek	Casgevy (Exa-cel) Lyfgenia (Lovo-cel)	Lenmeldy (atidarsgene autotemcel)	<b>Kebilidi</b> (Upstaza)
Duchenne Muscular Dystrophy children 4-5 years old	Hemophilia A – adults with severe bleeding	Dystrophic epidermolysis bullosa (DEB)	Sickle Cell Disease >12 years old - w/ crisis - w/o crisis	Metachromatic Leuko- dystrophy	Aromatic L- amino acid decarboxylase (AADC) deficiency
\$3,200,000	\$2,900,000	\$632,000	\$2.2M - \$3.3M	\$4,250,000	\$3,700,000
1:3,500	1:5,600	1:51,000	1:3,300	1:40,000 — 1:60,000	1:64k-90k births
1	1	0	0	0	0

- Estimated cost as published by the drug manufacturer at the time of FDA approval.
- Prevalence indicates prevalence of established medical cases in the United States
- # Members indicates the number of enrolled members on the plan who match the diagnosis code and identify with the FDA approved drug indication.



## **Risk & Chronic Conditions**

Member risk profile Very High 30.4 High 9.8

Concurrent 1.17 | Predicted 1.20 | Employees 1.31 / 1.38 | Spouses 1.74 / 1.71

Mod High 2.3 Very Low 0.1 Low 0.5 Mod 0.9 197/ \$51.0K 2,173/ \$10.1K 2,186/ \$1.9K 4,315/\$419 73/ \$195.6K 565/ \$3.2K



## Top chronic conditions Previous: 01/23-12/23 | Current: 01/24-12/24

Behavioral Health				
Members	1,448			
Risk	1.6			
PMPM Med	\$17			
PMPM Rx	\$4			
150/ of mambara bays a				

15% of members have a **Behavioral Health claim** 

Diabetes		
Members	479	
Risk	3.2	
PMPM Med	\$4	
PMPM Rx	\$39	
5% of members have a		

**Diabetes claim** 

Hypertension			
Members	838		
Risk	2.5		
PMPM Med	\$2		
<b>PMPM Rx</b> \$0.25			
9% of members have a			

**Hypertension claim** 

Musculoskeletai		
Members	1,000	
Risk	2.6	
PMPM Med	\$24	
PMPM Rx		

11% of members have a

**Chronic Musculoskeletal** claim

50% of members have a chronic condition





## **♣** Preventive Care

### 50% members

had a preventive visit

764

Prev. visits +5% from prior



## **Primary Care / PCP**

### 63% members

had a primary care visit

2.163

PCP visits +5% from prior



## **Well-being programs**

Comprehensive programs with optimal engagement can help shift members to a lower risk status ideally leading to savings.


 Current programs in place: Anthem: Hinge Health, Total Health Total You, Sydney Health, LHO virtual medical and MH/BH services, EAP

Proprietary and confidential Marsh & McLennan Agency LLC


## **Chronic Conditions by Generation**




## Medical costs paid per member per month by generation




## Members with behavioral health conditions (per 1,000 members)



## Members with diabetes (per 1,000 members)



## Members with chronic musculoskeletal conditions (per 1,000 members)



## 2025 Data Driven Action Plan

## Transforming Data into Actionable Strategies

## **Well-being & Chronic Condition Management**

50% of total member population managing one or more chronic condition; Cancer included in top HCC diagnoses;50% preventive care and PCP utilization

### **Robust Communication Campaign**

- WWFY's Marketplace Resource Centralized Benefits Page
- Teladoc's diabetes management program services vs Virta
- Leverage Anthem resources and MMA's eMMpower toolkit: Customize by generations
  - Millennials and Gen Z on importance of preventive care, avoidable ER, and available MH/BH resources
  - Gen X and Boomers: Available chronic condition management programs: Diabetes, MSK, and Metabolic Syndrome
  - Vera: new PCP provider locations: currently in Scott's Addition, coming to Chesterfield and Short Pump this Fall
  - Consider Anthem's preferred formulary for biosimilars (Humira, Stelara)

### Mental/Behavioral Health

Remains top chronic condition YOY; 15% of total covered members; significant increase in medical PMPM (82% over a three-year trend)

Promote Anthem's available programs, and resources:

- Consider a virtual mental health panel event
- Schedule call with Anthem to learn about new point solution partnerships: Full list located in Appendix
  - LHO: Virtual MH/BH services
  - Aspire365: Virtual and In-home mental health, substance use and co-occurring disorders treatment (13+ years of age)
  - Headway: Virtual and In-person therapy services and medication management (1+ years of age)
  - Rula: Individual and family therapy, psychiatric care and medication management



## Current preventive care and chronic condition management programs

Population Health and Chronic Conditions	Program
Chronic Condition Management Metabolic Syndrome: Diabetes, Hypertension, Hyperlipidemia, Weight  Preventive Care and Well-being	<ul> <li>Anthem:</li> <li>Total Health Total You</li> <li>Sydney Health</li> <li>LHO Medical services</li> <li>Cancer Care Navigator</li> <li>Anthem Health Guide</li> <li>Condition Care: Diabetes, Asthma, COPD, Heart Failure and Coronary Artery Disease</li> <li>Lark Diabetes Prevention Program</li> </ul>
Musculoskeletal	Anthem  • Hinge Health virtual PT services  • MSK Toolkit – Time Well Spent <a href="https://timewellspent.anthem.com">https://timewellspent.anthem.com</a> ; 4Q 2025 Well-being <a href="focus">Focus</a>
Mental/Behavioral Health	<ul> <li>Anthem:</li> <li>EAP</li> <li>LHO virtual MH/BH services</li> <li>Behavioral Health Advantage</li> <li>Learn to Live: Emotional Well-being Resources</li> <li>Point solutions: Rula: Virtual and in-home Individual, Couples and Family Therapy services (5+ years of age); BrightView Virtual &amp; In-person substance use disorder support (18+ years of age); Aspire365 Virtual and In-home mental health and substance use support (13+ yrs of age) etc.</li> </ul>

## Introducing eMMpower

Your one-stop-shop for well-being resources, education and toolkits. Here you will find fully vetted resources that will help support:

- Well-being strategy development
- Tools to help build a well-being program
- Turnkey employee communication samples
- Compliance requirements

"When employees feel supported, in all aspects of their lives, it resonates throughout an organization."

- Dave Eslick, CEO, Marsh McLennan Agency

## **Accessing eMMpower:**

eMMpowermma.clientportalonline.com
Username: emmpower@zywave.com
Password:MMAemmpower1

Marsh & McLennan Agency LLC